Abstract | BACKGROUND: METHODS: RESULTS: We found a subgroup of patients with high MMP-13 expression level in their tumors (>/=90% MMP-13-positive tumor cells) associated with unfavorable prognosis (median overall survival [OS], 11.8 vs 19.6 months, p = .032). In addition, the median disease-specific survival (DSS) time was markedly reduced in this subgroup (13.8 months vs 40.7 months, p = .062). When the subgroup of patients treated with a curative intent was studied, the same association was found in OS (13.8 vs 24.6 months, p = .023) and DSS (p = .004). In addition, there was a trend for association between >/=90% MMP-13 positivity and a recurrent tumor (p = .078) in curatively treated patients. CONCLUSIONS: The short survival time associated with high MMP-13 expression levels could not be predicted by tumor size or local lymph node invasion. These results show that a high MMP-13 expression level is associated with aggressiveness of HNSCC and may have prognostic value in patient evaluation.
|
Authors | Marjaana Luukkaa, Pia Vihinen, Pauliina Kronqvist, Tero Vahlberg, Seppo Pyrhönen, Veli-Matti Kähäri, Reidar Grénman |
Journal | Head & neck
(Head Neck)
Vol. 28
Issue 3
Pg. 225-34
(Mar 2006)
ISSN: 1043-3074 [Print] United States |
PMID | 16302191
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | (c) 2005 Wiley Periodicals, Inc. |
Chemical References |
- Collagenases
- MMP13 protein, human
- Matrix Metalloproteinase 13
|
Topics |
- Aged
- Carcinoma, Squamous Cell
(enzymology, mortality, therapy)
- Collagenases
(metabolism)
- Female
- Humans
- Male
- Matrix Metalloproteinase 13
- Mouth Neoplasms
(enzymology, mortality, therapy)
- Neoplasm Recurrence, Local
(enzymology)
- Pharyngeal Neoplasms
(enzymology, mortality, therapy)
- Prognosis
- Radiotherapy, Adjuvant
|